Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-01-30
2007-01-30
Tate, Christopher R. (Department: 1655)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S029000
Reexamination Certificate
active
10820582
ABSTRACT:
Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind spingolipids or sphingolipid metabolites. In one embodiment the agent is an antibody or antibody derivative. In some embodiments, the agent is a receptor of a sphingolipid or a sphingolipid metabolite. Also disclosed are methods for identifying and isolating therapeutic agents.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igarashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igarashi et al.
patent: 5430169 (1995-07-01), Boumendjel et al.
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5631394 (1997-05-01), Wei et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 5912144 (1999-06-01), Au-Young et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6352844 (2002-03-01), Maurer et al.
patent: 6423527 (2002-07-01), Saba et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 6534323 (2003-03-01), Sabbadini
patent: 2001/0041688 (2001-11-01), Waeber et al.
patent: 2003/0219782 (2003-11-01), Saba et al.
patent: 0173648 (1986-03-01), None
patent: 0173663 (1986-03-01), None
patent: 09-110722 (1987-04-01), None
patent: WO 97/44019 (1997-11-01), None
patent: WO 98/03529 (1998-01-01), None
patent: WO 98/28445 (1998-07-01), None
patent: WO 99/07855 (1998-08-01), None
patent: WO 98/40349 (1998-09-01), None
patent: WO 99/12890 (1999-03-01), None
patent: WO 99/16888 (1999-04-01), None
patent: WO 99/33972 (1999-07-01), None
patent: WO 99/38983 (1999-08-01), None
patent: WO 99/41265 (1999-08-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/00593 (2000-01-01), None
patent: WO 00/21919 (2000-04-01), None
patent: WO 00/52173 (2000-09-01), None
patent: WO 00 56135 (2000-09-01), None
patent: WO 00/58448 (2000-10-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 98/57179 (2000-10-01), None
patent: WO 00/70028 (2000-11-01), None
patent: WO 00/72833 (2000-12-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 01/04139 (2001-01-01), None
patent: WO 01/07418 (2001-02-01), None
patent: WO 01/31029 (2001-05-01), None
patent: WO 01 37836 (2001-05-01), None
patent: WO 01/38295 (2001-05-01), None
patent: WO 01/55410 (2001-08-01), None
patent: WO 01/57057 (2001-08-01), None
patent: WO 01/60990 (2001-08-01), None
patent: WO 01 71045 (2001-09-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 01/80903 (2001-11-01), None
patent: WO 01/85953 (2001-11-01), None
Sommers et al, Pro. Soc. Exp. Biol. Med., V.114, p. 350-352, (1963).
Urdal, D. Dissertation Abstracts International. 1980. vol. 41, No. 11B, p. 4062I DISSABS Abstract enclosed.
Visentin et al. Cancer Cell. 2006. vol. 9, No. 3, pp. 225-238, BIOBASE Abstract enclosed.
Milstien et al. Cancer Cell. 2006. vol. 9, No. 3, pp. 148-150. BIOBASE Abstract enclosed.
Abe, et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney International, 57:446-454 (2000).
Abe, et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”Journal of Lipid Research, 36:611-621 (1995).
Abe, et al., “Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors,”Analytical Biochemistry, 287:344-347 (2000).
An, et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic Acit,”J. Biol. Chem., 273:7906-7910 (1998).
An, et al., “Identification of CDNAs encoding two G protein-coupled receptors for lysosphingolipids,”FEBS Letts., 417:279-282 (1997).
An, et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem., 275:288-296 (2000).
Ancellin, et al., “Extracellular export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”JBC Papers in Press, Published Dec. 10, 2001 (manuscript M102841200).
Andrieu-Abadie, et al., “L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J., 13:1501-1510 (1999).
Arenz, et al., “Manumycin A and Its Analogues Are Irreversible Inhibitors of Neutral Sphingomyelinase,”ChemiBiochem., 2:141-143 (2001).
Arenz, et al., “Synthese des ersten selektiven irreverilben inhibitors der neutralen Sphingomyelinase,”Angew Chem., 112:1498-1500 (2000) (GERMAN).
Arenz, et al., “Synthesis and Biochemical Investigation of Scyphostatin Analogues as Inhibitors of Neutral Sphingomyelinase,”Bioorganic&Medicinal Chemistry, 9:2901-2904 (2001).
Arenz, et al., “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Eur. J. Org. Chem., 137-140 (2001).
Ariga, et al., “Role of Sphingolipid-mediated cell death in neurodegenerative diseases,”Journal of Lipid Research, 39:1-16 (1998).
Bajjalieh, et al., “Ceramide Kinase,”Methods in Enzymology, 311:207-215 (1999).
Bawab, et al., “Molecular Cloning and Characterization of a Human Mitochondrial Ceramidase,”J. Biol. Chem., 275:21508-21513 (2000).
Bernardo, et al., “Purification and Characterization of a Magnesium-dependent Neutral Sphingomyelinase from Bovine Brain,”J. Biol. Chem., 275:7641-7647 (2000).
Betto, et al., “Sphingosylphosphocholine modulates the ryanodine receptor/calcium-release channel of cardiac sarcoplasmic reticulum membranes,”Biochem. J., 322:327-333 (1997).
Bielawska, et al., “(1S, 2R)-D-erhthro-2-(N-Myristoylamino)-1-phenyl-1-propanol as an Inhibitor of Ceramidase,”J. Biol. Chem., 271:12646-12654 (1996).
Bielawska, et al., “Ceramide Is Involved in Triggering of Cardiomyocyte Apoptosis Induced by Ischemia and Reperfusion,”Am. J. Pathol., 151(5):1257-1263 (1997).
Boudker, et al., “Detection and Characterization of Ceramide-1-phosphate Phosphatase Activity in Rat Liver Plasma Membrane,”J. Biol. Chem., 268:22150-22155 (1993).
Brady, et al., “The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease,”Proc. Natl. Acad. Sci. USA, 55(2):366-369 (1966).
Brindley, et al., “Analysis of Ceramide 1-phosphate and Sphingosine-1-phosphate Phosphatase Activities,”Methods in Enzymology, 311:233-244 (1999).
Brownlee, C., “Intracellular signalling: sphingosine-1-phosphate branches out,”Current Biology, 11:R535-R538 (2001).
Burto
BioTechnology Law Group
Chambers Daniel M.
Lpath Therapeutics, Inc.
Tate Christopher R.
LandOfFree
Compositions and methods for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819610